Stocks & Indices Unverified First seen 2026-10-12 13:27 UTC

First Tracks Biotherapeutics IPO stock surges over 25% on celiac disease results

Investor's Business Daily reported that First Tracks Biotherapeutics, an AnaptysBio spinoff, posted "impressive" results for its celiac disease treatment on Monday, sending the IPO stock up by double digits. The post states the stock skyrocketed more than 25%.

Why “Unverified”

Reported by Investor's Business Daily alone, with no second source or primary confirmation yet

1 independent source group across 1 post · evidence score 52/100. How labels work

What the sources claim

First Tracks Biotherapeutics posted impressive results for its celiac disease treatment on Monday.

“First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday”
Investor's Business Daily
The IPO stock surged by double digits, skyrocketing more than 25%.

“the IPO stock surged by double digits”
Investor's Business Daily

Sources

Investor's Business Daily newswire 2026-10-12 13:27 UTC
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%

More in Stocks & Indices

All Stocks & Indices stories →

Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-12 13:40 UTC. Labels are computed from the sources, not by the model.